Pulmonary Therapy View Homepage


Ontology type: schema:Periodical      Open Access: True


Journal Info

START YEAR

2015

PUBLISHER

Springer Healthcare

LANGUAGE

en

HOMEPAGE

http://link.springer.com/journal/41030

Recent publications latest 20 shown

  • 2021-10-26 Real-World Analysis of Treatment Patterns Among Hospitalized Patients with Pulmonary Arterial Hypertension
  • 2021-10-25 Cannabis and Lung Health: Does the Bad Outweigh the Good?
  • 2021-10-15 The Impact of Risk Factors on Treatment Outcomes of Nosocomial Pneumonia Due to Gram-Negative Bacteria in the Intensive Care Unit
  • 2021-10-13 The Effect of Adding a Training Device and Smartphone Application to Traditional Verbal Counseling in Asthmatic Children
  • 2021-09-27 Switching to the Dry-Powder Inhaler Easyhaler®: A Narrative Review of the Evidence
  • 2021-09-17 Impact of PIF, Inhalation Technique and Medication Adherence on Health Status and Exacerbations in COPD: Protocol of a Real-World Observational Study (PIFotal COPD Study)
  • 2021-08-31 Use of a Digital Chronic Obstructive Pulmonary Disease Respiratory Tracker in a Primary Care Setting: A Feasibility Study
  • 2021-08-18 CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis
  • 2021-08-16 Burden of Pneumonia Among Hospitalized Patients with Influenza: Real-World Evidence from a US Managed Care Population
  • 2021-08-11 Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective
  • 2021-07-14 Correction to: Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
  • 2021-07-07 Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD
  • 2021-06-26 Effects of Recombinant Human Angiotensin-Converting Enzyme 2 on Response to Acute Hypoxia and Exercise: A Randomised, Placebo-Controlled Study
  • 2021-06-21 Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial
  • 2021-06-18 A Comprehensive Review of Sarcoidosis Treatment for Pulmonologists
  • 2021-06-08 Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
  • 2021-06-06 A Comprehensive Review of Sarcoidosis Diagnosis and Monitoring for the Pulmonologist
  • 2021-06-04 Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer
  • 2021-05-15 Period-to-Period Variability of Moderate/Severe Obstructive Sleep Apnoea
  • 2021-05-11 Pulmonary Therapy Podcast—COVID-19: Research and Real-World Experiences from the Editorial Board
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "description": "

    Aims and Scope

    Pulmonary Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from clinical (all phases), observational, real-world, and health outcomes research around the use of pulmonary therapies, devices, and surgical techniques.

    Areas of focus include, but are not limited to: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other respiratory allergies; influenza, pneumococcal infection, respiratory syncytial virus and other respiratory infections; and inhalers and other device therapies.

    The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols\u00a0and short communications such as commentaries and editorials. Pulmonary Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals.

    Rapid Publication

    The journal\u2019s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3\u20134 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal\u2019s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of pulmonary therapies.

    Open Access

    All articles published by Pulmonary Therapy are open access.

    Personal Service

    The journal\u2019s dedicated in-house editorial team offer a personal \u201cconcierge service\u201d meaning authors will always have an editorial contact able to update them on the status of their manuscript.\u00a0 The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research.

    Digital Features and Plain Language Summaries

    Pulmonary Therapy\u00a0offers a range of additional features designed to increase the visibility, readership and educational value of the journal\u2019s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see \u2018Contact the Journal\u2019 for email address), and see the \u2018Guidelines for digital features and plain language summaries\u2019 document under \u2018Submission guidelines\u2019.

    Publication Fees

    Upon acceptance of an article, authors will be required to pay the mandatory\u00a0Rapid Service Fee\u00a0of $5100/ \u20ac4500. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis. Considering the time and effort required for a detailed peer review we also reward our regular reviewers with the opportunity to publish without the Rapid Service Fee\u00a0(pending peer review) for every three reviews completed per calendar year.\u00a0

    Peer Review Process

    Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.

    At least two extensive reviews are required to make the editorial decision. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor.

    Preprints

    We encourage posting of preprints of primary research manuscripts on preprint servers, authors\u2019 or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in one of our journals. Once the manuscript is published, it is the author\u2019s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website.

    Please\u00a0follow the link\u00a0for further information on preprint sharing:
    https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550

    Copyright

    Pulmonary Therapy's\u00a0content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.

    Contact

    For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.

    ", "id": "sg:journal.1136859", "inLanguage": [ "en" ], "isAccessibleForFree": true, "issn": [ "2364-1754", "2364-1746" ], "license": "Fully Open Access", "name": "Pulmonary Therapy", "productId": [ { "name": "dimensions_id", "type": "PropertyValue", "value": [ "136859" ] }, { "name": "lccn_id", "type": "PropertyValue", "value": [ "2017226592" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "101687144" ] } ], "publisher": { "name": "Springer Healthcare", "type": "Organization" }, "publisherImprint": "Adis", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1136859" ], "sdDataset": "journals", "sdDatePublished": "2021-11-01T19:07", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/journal/journal_0.jsonl", "startYear": "2015", "type": "Periodical", "url": "http://link.springer.com/journal/41030" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1136859'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1136859'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1136859'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1136859'


     

    This table displays all metadata directly associated to this object as RDF triples.

    34 TRIPLES      18 PREDICATES      22 URIs      18 LITERALS      5 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1136859 schema:description <p><b>Aims and Scope<br/></b><br/><i>Pulmonary Therapy</i> is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from clinical (all phases), observational, real-world, and health outcomes research around the use of pulmonary therapies, devices, and surgical techniques.<br/><br/>Areas of focus include, but are not limited to: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other respiratory allergies; influenza, pneumococcal infection, respiratory syncytial virus and other respiratory infections; and inhalers and other device therapies.<br/><br/>The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. <i>Pulmonary Therapy</i> will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. <br/><br/><b>Rapid Publication</b><br/><br/>The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of pulmonary therapies.</p><p><b>Open Access</b></p><p>All articles published by <i>Pulmonary Therapy</i> are open access.</p><p><b>Personal Service</b><br/><br/>The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript.  The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. <br/><br/><b>Digital Features</b><b> and Plain Language Summaries</b><br/><br/><i>Pulmonary Therapy</i> offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’.<br/><br/><b>Publication Fees<br/></b><br/>Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of $5100/ €4500. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis. Considering the time and effort required for a detailed peer review we also reward our regular reviewers with the opportunity to publish without the Rapid Service Fee (pending peer review) for every three reviews completed per calendar year.  <br/><br/><b>Peer Review Process</b><br/><br/>Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.<br/><br/>At least two extensive reviews are required to make the editorial decision. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor.<br/><br/><b>Preprints<br/></b><br/>We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in one of our journals. Once the manuscript is published, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website.</p><p>Please follow the link for further information on preprint sharing: <br/>https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550<br/><br/><b>Copyright</b><br/><br/><i>Pulmonary Therapy's </i>content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.<br/><br/><b>Contact<br/><br/></b>For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.</p>
    2 schema:inLanguage en
    3 schema:isAccessibleForFree true
    4 schema:issn 2364-1746
    5 2364-1754
    6 schema:license Fully Open Access
    7 schema:name Pulmonary Therapy
    8 schema:productId N0f459d6c2d944a4fbba2aefca96614c9
    9 N3b84b13e8aac4b898a5744b3250bab44
    10 Nd2c0ce39ec9d4b8ea144b40e62616e3f
    11 schema:publisher N01c4ee1445304d9fbdfcf1775a155bc3
    12 schema:publisherImprint Adis
    13 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1136859
    14 schema:sdDatePublished 2021-11-01T19:07
    15 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    16 schema:sdPublisher N3a70be98c4874f79931a8498547249d7
    17 schema:startYear 2015
    18 schema:url http://link.springer.com/journal/41030
    19 sgo:license sg:explorer/license/
    20 sgo:sdDataset journals
    21 rdf:type schema:Periodical
    22 N01c4ee1445304d9fbdfcf1775a155bc3 schema:name Springer Healthcare
    23 rdf:type schema:Organization
    24 N0f459d6c2d944a4fbba2aefca96614c9 schema:name dimensions_id
    25 schema:value 136859
    26 rdf:type schema:PropertyValue
    27 N3a70be98c4874f79931a8498547249d7 schema:name Springer Nature - SN SciGraph project
    28 rdf:type schema:Organization
    29 N3b84b13e8aac4b898a5744b3250bab44 schema:name nlm_unique_id
    30 schema:value 101687144
    31 rdf:type schema:PropertyValue
    32 Nd2c0ce39ec9d4b8ea144b40e62616e3f schema:name lccn_id
    33 schema:value 2017226592
    34 rdf:type schema:PropertyValue
     




    Preview window. Press ESC to close (or click here)


    ...